The earnings call presented a predominantly positive outlook with significant revenue growth, a record number of new customer signings, and the landmark AstraZeneca partnership. However, challenges persist with BioPharma revenue headwinds and increased operating expenses.

Company Guidance -

Q3 2025

During the SOPHiA GENETICS second quarter 2025 earnings call, the company reported a 16% year-over-year revenue growth, reaching $18.3 million, with a notable 20% increase in revenue excluding BioPharma, despite challenges in that sector. The company also highlighted a significant decrease in cash burn, down to $8.7 million—a 35% improvement from the prior year. SOPHiA signed 35 new customers in Q2, bringing the total to 63 new customers for the year, and implemented 18 new customers, up slightly from the prior year. The U.S. market saw a 19% revenue growth, excluding BioPharma, while the Asia Pacific region posted a 33% growth. The company achieved a 74.4% adjusted gross margin, up 120 basis points year-over-year, and announced a landmark contract with AstraZeneca, focusing on leveraging SOPHiA's AI to advance breast cancer treatment. SOPHiA also reported a strong pipeline, with the average contract value of new business up over 100% year-on-year, signaling continued momentum and growth prospects.

Revenue Growth

Total revenue grew 16% year-over-year. Excluding BioPharma, revenue grew over 20%, signaling a return to near historical growth levels.

New Customer Signings

A record 35 new customers were signed in Q2, bringing the total to 63 new customers in 2025. Implemented 18 new customers in Q2.

U.S. Market Expansion

U.S. revenue, excluding BioPharma, grew more than 19% year-over-year, with significant new customer signings including UC Irvine and the University of Alabama, Birmingham.

Global Adoption of MSK-ACCESS

Signed 11 new customers for MSK-ACCESS, bringing the total number to 50 customers globally.

Partnership with AstraZeneca

Signed the largest contract in SOPHiA GENETICS' history with AstraZeneca, focusing on AI-powered predictive models for breast cancer treatment.

Improved Cash Burn and Gross Margin

Cash burn decreased to $8.7 million, a 35% year-over-year improvement. Adjusted gross margin improved to 74.4%, up 120 basis points year-over-year.

SOPHiA GENETICS (SOPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SOPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.23 / -	-0.28	―	―	―
Aug 05, 2025	2025 (Q2)	-0.21 / -0.33	-0.23	-43.48% (-0.10)
May 06, 2025	2025 (Q1)	-0.22 / -0.26	-0.21	-23.81% (-0.05)
Mar 04, 2025	2024 (Q4)	-0.20 / -0.23	-0.37	37.84% (+0.14)
Nov 05, 2024	2024 (Q3)	-0.22 / -0.28	-0.21	-33.33% (-0.07)
Aug 06, 2024	2024 (Q2)	-0.27 / -0.23	-0.33	30.30% (+0.10)
May 07, 2024	2024 (Q1)	-0.24 / -0.21	-0.31	32.26% (+0.10)
Mar 05, 2024	2023 (Q4)	-0.22 / -0.37	-0.17	-117.65% (-0.20)	―
Nov 07, 2023	2023 (Q3)	-0.30 / -0.21	-0.3	30.00% (+0.09)	―
Aug 08, 2023	2023 (Q2)	-0.29 / -0.33	-0.39	15.38% (+0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SOPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$3.30	$3.42	+3.64%
May 06, 2025	$3.14	$3.00	-4.46%
Mar 04, 2025	$3.57	$3.10	-13.17%
Nov 05, 2024	$3.75	$3.75	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sophia Genetics Sa (SOPH) report earnings?

Sophia Genetics Sa (SOPH) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is Sophia Genetics Sa (SOPH) earnings time?

Sophia Genetics Sa (SOPH) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SOPH EPS forecast?

SOPH EPS forecast for the fiscal quarter 2025 (Q3) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing